Personalized Decision-Making in the Treatment of Early-Stage Breast Cancer

Tarah J. Ballinger, MD

Disclosures

July 29, 2022

Tarah J. Ballinger, MD, discusses what she has learned from her day-to-day patient interactions and the nuanced decisions that patients with early-stage breast cancer make as they share in the decision-making process. She considers the potential consequences of personalized patient decisions, such as de-escalation of therapy to avoid long-term toxicities, and patients who develop early recurrences or metastatic disease and could have benefited from more aggressive therapy upfront.

Dr Ballinger also recounts one of her patients who decided to pause adjuvant endocrine therapy to pursue fertility options and how that patient thinks about "how one decision is motivated by fear and one choice is motivated by hope."

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....